ABG Sundal Collier acted as Sole Bookrunner in connection with the SEK 85 million directed share issue in BioInvent
BioInvent International AB (”BioInvent”) today announces that the company has successfully completed a directed share issue of 45,704,281 new shares at a subscription price of SEK 1.85 per share, which means that the Company will receive gross proceeds of approximately SEK 85 million. The price in the Issue has been determined through an accelerated bookbuilding procedure.
The net capital from the Issue is mainly intended to finance BioInvent’s costs related to progress and to expand the clinical development of its lead antibody BI-1206 for treatment of haematological cancers, as well as continued development of the Company’s prioritized pre-clinical projects, developed on its own or together with partners. In addition, a strengthened financial position enables increased strategic flexibility and improved ability to negotiate with potential partners.